8-K: Replimune Amends Loan, Reports Q3 Results, Eyes RP1 FDA Decision

Replimune Group, Inc. announced an amendment to its loan agreement with Hercules Capital, extended its cash runway, and reported fiscal third quarter 2026 financial results while awaiting an FDA decision on RP1 for advanced melanoma.

Summary

• Replimune amended its loan agreement with Hercules Capital, Inc. on January 29, 2026, extending the revenue milestone date to September 30, 2027, and the debt amortization date to October 1, 2027.
• The third loan tranche advance increased from $30 million to $35 million and was funded on January 29, 2026, with availability extended to June 15, 2026.
• The fourth tranche advance decreased from $50 million to $30 million, with availability extended to September 30, 2026, or 60 days post-approval milestone.
• The fifth tranche advance of $50 million had its availability extended to December 31, 2027, or 60 days post-revenue milestone.
• The sixth tranche advance increased from $25 million to $40 million.
• The interest rate was amended to be the greater of 8.50% or the Prime Rate plus 1.75%.
• The FDA accepted the Biologics License Application (BLA) resubmission for RP1 in anti-PD-1 failed melanoma in October 2025, with a Prescription Drug User Fee Act (PDUFA) target action date of April 10, 2026.
• Cash, cash equivalents, and short-term investments were $269.1 million as of December 31, 2025, down from $483.8 million as of March 31, 2025.
• Research and development expenses increased to $53.1 million for the fiscal third quarter ended December 31, 2025, from $48.0 million in the prior year period.
• Selling, general and administrative expenses were $18.7 million for the fiscal third quarter ended December 31, 2025, compared to $18.0 million in the prior year period.
• Net loss for the fiscal third quarter ended December 31, 2025, was $70.9 million, an increase from $66.3 million for the same period in the prior year.
• The company believes its existing cash runway extends late into the first quarter of calendar 2027, excluding potential revenue.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed filing. The positive regulatory progress for RP1 and extended cash runway are significant, but the increased net loss and substantial cash burn remain a concern, indicating continued high operational costs ahead of potential commercialization.

Positives

• FDA accepted the Biologics License Application (BLA) resubmission for RP1 in anti-PD-1 failed melanoma in October 2025, setting a PDUFA target action date of April 10, 2026.
• The loan agreement amendment provides an immediate draw of $35 million and potential for an additional $120 million at post-approval milestones.
• The cash runway has been extended late into the first quarter of 2027.
• The debt amortization date was extended from October 1, 2026, to October 1, 2027.
• RP1 monotherapy showed robust anti-tumor activity in locally advanced cutaneous squamous cell carcinoma (CSCC) with an objective response rate (ORR) of 34.6% and a 2-year duration of response of 61.0%.
• RP1 combined with nivolumab showed an objective response rate (ORR) of 44% in acral melanoma patients who failed anti-PD-1 treatment, with a median duration of response of 11.9 months.
• RP1 plus nivolumab provided responses across multiple advanced non-melanoma skin cancer (NMSC) tumor types, including anti-PD-1 naive and failed disease, and both locally advanced and metastatic disease, with ORRs ranging from 15.2% to 100%.

Negatives

• Net loss increased to $70.9 million for the fiscal third quarter ended December 31, 2025, from $66.3 million in the prior year period.
• Cash, cash equivalents, and short-term investments decreased to $269.1 million as of December 31, 2025, from $483.8 million as of March 31, 2025, indicating significant cash burn.
• Research and development expenses increased to $53.1 million for the fiscal third quarter ended December 31, 2025, from $48.0 million in the prior year, driven by increased study costs and personnel.
• The interest rate on the loan agreement was amended to be the greater of 8.50% or the Prime Rate plus 1.75%, which could increase interest expenses.
• The fourth tranche advance under the loan agreement was decreased from $50 million to $30 million.
• Enrollment in the IGNYTE clinical trial cohort in NMSC was stopped in Q4 2025.

Risks

• The outcome of the FDA's review process for the RP1 BLA and the potential for approval.
• Ability to generate positive clinical trial results for product candidates.
• Costs and timing of operating the in-house manufacturing facility.
• Timing and scope of regulatory approvals.
• Availability of combination therapies needed to conduct clinical trials.
• Changes in laws and regulations.
• Competitive pressures in the biotechnology industry.
• Ability to identify additional product candidates.
• Impact of political and global macro factors, including public health issues and ongoing conflicts.

Future Outlook

Replimune anticipates a potential commercial launch of RP1 in advanced melanoma, if approved by the FDA by the April 10, 2026 PDUFA target action date. The company is actively enrolling patients in its registration-directed Phase 2/3 trial for RP2 in metastatic uveal melanoma, with a Phase 2/3 transition expected in Q1 2027, and plans to release RP2 monotherapy data in liver-focused studies by the end of 2026. The company has extended its cash runway late into the first quarter of 2027 to support these operations and potential commercialization.

Management Comments

• "We have been engaged with the FDA in the review of the BLA resubmission for RP1."
• "Advanced melanoma patients can progress quickly and are in urgent need of safe and effective treatment options."
• "Our team remains ready to launch RP1 with commercial supply produced and the commercial organization prepared to engage with our target accounts rapidly, assuming FDA approval."

Industry Context

StockSavvy.ai notes that the oncolytic immunotherapy space, particularly for advanced melanoma and other skin cancers, remains highly competitive with significant unmet needs. Replimune's progress with RP1, especially the FDA's acceptance of the BLA resubmission and the upcoming PDUFA date, positions it as a potential new entrant in a market dominated by established checkpoint inhibitors. The continued development of RP2 for uveal melanoma and liver-focused studies indicates a broader strategy to leverage its RPx platform across multiple difficult-to-treat cancers, aligning with the industry trend of exploring combination therapies and novel mechanisms of action.

Comparison to Industry Standards

• The objective response rate (ORR) of 44% for RP1 plus nivolumab in anti-PD-1 failed acral melanoma, with a median duration of response of 11.9 months, is a notable result in a challenging patient population. For comparison, other therapies in similar advanced melanoma settings, especially after anti-PD-1 failure, often show lower response rates or shorter durations. For instance, some salvage therapies might yield ORRs in the 10-20% range.
• The ORR of 34.6% and 2-year duration of response of 61.0% for RP1 monotherapy in locally advanced cutaneous squamous cell carcinoma (CSCC) post-organ transplant is significant, as immunocompromised patients often have limited treatment options and higher recurrence rates. This compares favorably to historical data for systemic therapies in this specific high-risk population.
• The reported ORRs for RP1 plus nivolumab across various non-melanoma skin cancers (NMSC), ranging from 15.2% to 100%, demonstrate broad activity. While direct comparisons are difficult without specific trial designs, these rates suggest competitive efficacy, particularly in anti-PD-1 naive settings.

Stakeholder Impact

• Shareholders: Potential for significant value creation if RP1 receives FDA approval, but ongoing cash burn and increased net loss could dilute value or necessitate future financing. The extended cash runway provides some stability.
• Patients: Potential for a new, effective treatment option (RP1) for advanced melanoma and other skin cancers, particularly for those who have failed previous therapies.
• Lenders (Hercules Capital, Inc.): Amended loan terms provide extended repayment schedules and adjusted tranche availability, reflecting ongoing partnership and risk assessment.
• Employees: Continued investment in R&D and commercial readiness suggests job stability and potential growth, especially with a successful RP1 launch.

Next Steps

• FDA Prescription Drug User Fee Act (PDUFA) target action date for RP1 in advanced melanoma on April 10, 2026.
• Potential commercial launch of RP1 if approved by the FDA.
• Continued enrollment in the global Phase 3 IGNYTE-3 confirmatory study for RP1 in advanced melanoma.
• Continued enrollment in the registration-directed Phase 2/3 REVEAL trial of RP2 in metastatic uveal melanoma, with Phase 2/3 transition expected in Q1 2027.
• Data planned by the end of 2026 for RP2 as monotherapy in liver-focused studies.
• Ongoing evaluation of RP2 combined with durvalumab in biliary tract cancer.
• Filing of the full text of the Third Amendment to Loan and Security Agreement as an exhibit to the company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2025.

Key Dates

Recommendation

The filing presents a mixed bag for investors. The upcoming PDUFA date for RP1 is a major near-term catalyst that could significantly boost the stock if approved, and the extended cash runway provides some operational breathing room. However, the substantial cash burn and increased net loss highlight the financial pressures of a clinical-stage biotech. While the clinical data for RP1 and RP2 are promising, the financial performance suggests a 'hold' position, awaiting the critical FDA decision and further clarity on commercialization prospects and future financing needs before making a more definitive move.

Keywords

Biotechnology, Oncology, Immunotherapy, Melanoma, FDA Approval, Clinical Trials, RP1, RP2, Financial Results, Loan Agreement, Cash Runway, Oncolytic Virus, Skin Cancer